# Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

> **NCT01120223** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 78 (actual)

## Conditions studied

- Scalp Psoriasis

## Interventions

- **DRUG:** LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)

## Key facts

- **NCT ID:** NCT01120223
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01120223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01120223, "Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01120223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*